Most Read

These patients have inadequate response to corticosteroids or other systemic therapies. Jakavi, an oral JAK 1 and JAK 2 tyrosine kinases inhibitor, was licensed by Novartis from Incyte

Other new investors Alpha Wave Ventures, NexPoint also participated in the round along with existing investors Morningside Ventures, Seligman Investments, and Tao Capital Partners. Apnimed will use the

This is the third orphan drug designation received by Sapience for ST101, a first-in-class peptide antagonist of C/EBPβ. The FDA granted orphan designations to ST101 for AML treatment

With over a hundred years of experience, Intravacc is a contract development and manufacturing organization (CDMO) of vaccines against infectious diseases. A vaccine company in China, Zhifei Lvzhu

Qelbree now received approval for ADHD treatment in children starting at the age of six, adolescents as well as adults. Supernus Pharmaceuticals president and CEO Jack Khattar said:

This marketing authorisation is applicable for use of Kapruvia in all member states of the European Union besides Iceland, Liechtenstein and Norway. The approval comes after the US

An orally disintegrating tablet and a calcitonin gene-related peptide (CGRP) receptor antagonist, Vydrua got the marketing authorisation for acute treatment of migraine with or without aura, and prophylaxis

This treatment is meant for patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer patients who have earlier received a systemic therapy in

The move supports the indication of a single priming anti-CTLA4 antibody dose added to the human monoclonal antibody Imfinzi (durvalumab) to treat HCC patients. AstraZeneca also submitted a